Hospitals caring for patients infected with the highly infectious omicron variant of COVID-19 say they are very relieved to be getting 340B pricing finally on Gilead’s injectable antiviral medication Veklury (remdesivir).
On Friday, the U.S. Food and Drug Administration (FDA) approved Veklury for administration to outpatients with mild-to-moderate COVID-19. It previously was approved for inpatient administration only. 340B discounts apply to covered outpatient drugs only.
Hospitals filled with patients infected with the highly infectious omicron variant of COVID-19 say they are very relieved to be getting 340B pricing finally on Gilead’s injectable antiviral medication Veklury (remdesivir).
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
